Application of olsalazine sodium in preparation of medicines and health products for preventing and treating hyperuricemia and gout

A technology of hyperuricemia and olsalazide sodium, which is applied in the field of pharmaceuticals, can solve the problems of epidermal necrosis, xanthine nephropathy and stones, and high mortality of hypersensitivity reactions, so as to save research and development costs and shorten research and development the effect of time

Inactive Publication Date: 2017-01-25
KUNMING MEDICAL UNIVERSITY +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Allopurinol is a purine analogue and a competitive XO inhibitor, but allopurinol can easily cause xanthine nephropathy and calculus (Zhu Shenyin, Zhou Yuanda, Du Guanhua. Advances in research on drugs for the prevention and treatment of gout[J] .Medical Herald 2006,25:(8):803-806.) and hypersensitivity reactions, and the mortality rate of hypersensitivity reactions is extremely high, especially HLA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of olsalazine sodium in preparation of medicines and health products for preventing and treating hyperuricemia and gout
  • Application of olsalazine sodium in preparation of medicines and health products for preventing and treating hyperuricemia and gout
  • Application of olsalazine sodium in preparation of medicines and health products for preventing and treating hyperuricemia and gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] 1. Inhibitory effect of inventive compound on xanthine oxidase

[0024] Xanthine oxidase (EC 1.1.3.22) is a product of Sigma Company, prepared with sodium pyrophosphate buffer solution to an appropriate concentration for use. Osalazide sodium was prepared into a series of concentrations with sodium pyrophosphate buffer solution for future use. After incubating xanthine oxidase with serial concentrations of olsalazide sodium solution at 25°C for 15 min, refer to the literature method [Kong LD, Zhang Y, Pan X, Tan RX, and Cheng CHK (2000) Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis . Cell Mol Life Sci 57:500–505] Determination of the activity of xanthine oxidase, the results showed that olsalazide sodium had a strong inhibitory effect on the activity of xanthine oxidase, and its IC 50 is 9.8 micromol / L ( Figure 2~4 ), the suppression type is mixed suppression ( Figure 5-7 ).

[0025] 2. Effects o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of olsalazine sodium in preparation of medicines for preventing and treating hyperuricemia and gout. The olsalazine sodium obviously inhibits the activity of xanthine oxidase in vitro, has IC50 of 9.8mu mol/L, and is a hybrid type xanthine oxidase inhibitor. The in vivo study shows that intraperitoneal injection of the 5.0mg/kg compound obviously reduces the level of serum uric acid of an oteracil potassium induced hyperuricemia mouse, and the dosage for reducing serum uric acid is very less than the dosage for treating ulcerative colitis clinically; and the olsalazine sodium has the characteristics of high efficiency and low toxicity and can be used for preparing medicines and health products for preventing and treating hyperuricemia and gout.

Description

technical field [0001] The invention belongs to medicines, in particular to medicines for preparing and preventing hyperuricemia and gout. Background technique [0002] Gout is a metabolic disease that seriously threatens human health. The high incidence age of the disease is middle-aged and elderly men and postmenopausal women. It is listed as one of the 20 chronic diseases in the 21st century. Uric acid (UA) is the end product of purine metabolism in the human body. It is decomposed into soluble allantoin and excreted from the body. It is an important measure to reduce and control blood uric acid level and treat and prevent gout. However, the human body lacks uric acid decomposing enzymes, and the result of accumulation makes it very easy to form hyperuricemia. As an index for the treatment of gout, the European League Against Rheumatism and the American College of Rheumatology recommend that the blood uric acid index should not be higher than 6 mg / dl. [0003] Xanthin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/655A61P19/06A23L33/00
CPCA23V2002/00A61K31/655A23V2200/30A23V2250/02
Inventor 牛艳芬李玲李宏健高丽辉林华刘旭梁广锡王文汉林李家宓孔祥复
Owner KUNMING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap